Semaglutide dosage for type 2 diabetes: understanding the difference from weight-loss treatment

You've been prescribed Ozempic for diabetes and you're also reading about Wegovy, here's where the confusion starts

It happens often. Someone managing type 2 diabetes hears that semaglutide is now available as a weight-loss treatment, looks it up, and ends up on a page that talks about 0.25mg, 0.5mg, 1.7mg and 2.4mg doses, numbers that partly overlap with what their diabetes clinic mentioned but don't quite match. The reason is that Ozempic and Wegovy share the same molecule but are licensed for different purposes, titrated on different schedules, and regulated separately by the MHRA.

For type 2 diabetes, Ozempic is injected once weekly. Treatment typically begins at a low dose to allow the body to adjust, then steps up at intervals under the supervision of the prescriber managing your diabetes. The goal in that context is blood-glucose control, and the dose used may be lower than the weight-management maintenance dose. Rybelsus, the oral form, follows its own separate tablet schedule for diabetes and uses 3mg, 7mg and 14mg strengths, strengths that are entirely distinct from those of the Wegovy weight-loss tablet, which runs 1.5mg through to 25mg. The NHS medicines information for semaglutide explains these distinctions clearly and is the most straightforward starting point if you want an overview written for patients.

What this means in practice: the number on your Ozempic pen is not a direct translation to a Wegovy dose, and if you want to understand how semaglutide dosage is structured across its different uses, that gives useful context before discussing either pathway with your prescriber. If you are trying to understand how semaglutide dosing works specifically in the context of fat loss, that is a separate conversation from diabetes management that you should not assume maps across automatically. That is a conversation for your diabetes team.

What happens when type 2 diabetes and weight management overlap (and who prescribes what

Many people with type 2 diabetes also carry excess weight, and in that situation semaglutide can potentially serve both purposes) but only if the prescribing is done carefully by someone who knows the whole picture. The NICE appraisal of semaglutide for weight management (TA875) is specific: it recommends Wegovy within specialist weight management services, with multidisciplinary support, and not as a casual add-on to an existing diabetes prescription.

If your GP is already prescribing Ozempic for diabetes, switching to or adding Wegovy is not something to arrange independently through a private pharmacy without telling them. The two treatments could interact with your existing regimen, affect your blood-sugar readings, and require adjustment of other diabetes medicines including insulin. Your prescriber needs to know, and if they're not the one initiating the change, they still need to be informed.

For those without diabetes who are researching semaglutide purely for weight management, the dosing picture is different again. The page on semaglutide dosage for people without diabetes covers the weight-management pathway in more detail, and the overview of Wegovy doses sets out the full titration schedule as licensed in the UK.

Worth checking: if you are unsure which product is relevant to your situation, the frequently asked questions section on the nume site addresses some of the most common points of confusion.

Safety considerations specific to diabetes, and when to speak to someone urgently

Living with type 2 diabetes adds layers to the semaglutide safety picture that don't apply to people without the condition. The most immediately relevant is blood-sugar management: semaglutide on its own has a low risk of hypoglycaemia, but when combined with other glucose-lowering medicines (sulphonylureas, insulin) the risk rises, and your prescriber may need to adjust those doses when semaglutide is introduced or when the dose increases.

On a broader safety note, the MHRA published a Drug Safety Update in January 2026 highlighting acute pancreatitis as a known but infrequent side effect of GLP-1 medicines including semaglutide. Severe stomach pain that spreads to the back, with or without vomiting, warrants urgent medical attention rather than waiting to see if it settles. Report any suspected side effects through the MHRA's Yellow Card scheme, which also accepts reports from patients directly.

Pregnancy and breastfeeding: semaglutide is not recommended during pregnancy, while breastfeeding, or when trying to conceive. For women of childbearing age on semaglutide who are not planning a pregnancy, effective contraception is advised. NHS guidance notes that for tirzepatide specifically (a related but different medicine), oral contraceptive absorption may be affected, so a non-oral method is recommended during dose increases, this does not have the same established evidence base for semaglutide, but your prescriber is the right person to discuss your individual contraception needs. If you are considering weight management treatment as a separate matter, the consultation page at nume outlines the clinical process our GPhC-registered prescribers follow before any treatment begins.

What you can and cannot get from a private weight-loss pharmacy if you have type 2 diabetes

This is a question our prescribers hear regularly. The short answer is that a private online pharmacy licensed to dispense weight-management medicines (including Wegovy) can prescribe it to someone with type 2 diabetes provided the clinical picture is appropriate and the prescriber has the information they need. That includes knowledge of your current diabetes medicines, recent HbA1c results, and the prescriber's confidence that the addition is safe.

What we do not do is prescribe Ozempic or Rybelsus for type 2 diabetes: those medicines sit within a different clinical pathway and are dispensed through your GP or hospital team. If you are thinking about weight management support alongside your diabetes care, the right starting point is a conversation with your existing prescriber before or alongside any private consultation. The Wegovy treatment overview explains how the weight-management medicine works; if you are using or considering the higher-concentration pen, the guidance on how the semaglutide 5mg pen is dosed is worth reading before your consultation; and if you want to understand the full range of private options, the weight-loss treatments overview is a useful place to start.

One practical note: if you do decide to book a private consultation, do it on a day when you can reach your GP surgery too, ideally before the lunchtime rush. Having your current medicines list and a recent blood-test result to hand makes the clinical review faster and more thorough for everyone. If you'd like to know more about the prescribing team behind our consultations, the clinical team profile is there to read. And if you have a specific question before starting, our support team is available seven days a week.